Evolving Diagnostic and Management Advances in Coronary Heart Disease
Despite considerable improvement in diagnostic modalities and therapeutic options over the last few decades, the global burden of ischemic heart disease is steadily rising, remaining a major cause of death worldwide. Thus, new strategies are needed to lessen cardiovascular events. Researchers in dif...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/13/4/951 |
| _version_ | 1797604688485416960 |
|---|---|
| author | Matheus de Oliveira Laterza Ribeiro Vinícius Machado Correia Lucas Lentini Herling de Oliveira Paulo Rogério Soares Thiago Luis Scudeler |
| author_facet | Matheus de Oliveira Laterza Ribeiro Vinícius Machado Correia Lucas Lentini Herling de Oliveira Paulo Rogério Soares Thiago Luis Scudeler |
| author_sort | Matheus de Oliveira Laterza Ribeiro |
| collection | DOAJ |
| description | Despite considerable improvement in diagnostic modalities and therapeutic options over the last few decades, the global burden of ischemic heart disease is steadily rising, remaining a major cause of death worldwide. Thus, new strategies are needed to lessen cardiovascular events. Researchers in different areas such as biotechnology and tissue engineering have developed novel therapeutic strategies such as stem cells, nanotechnology, and robotic surgery, among others (3D printing and drugs). In addition, advances in bioengineering have led to the emergence of new diagnostic and prognostic techniques, such as quantitative flow ratio (QFR), and biomarkers for atherosclerosis. In this review, we explore novel diagnostic invasive and noninvasive modalities that allow a more detailed characterization of coronary disease. We delve into new technological revascularization procedures and pharmacological agents that target several residual cardiovascular risks, including inflammatory, thrombotic, and metabolic pathways. |
| first_indexed | 2024-03-11T04:50:18Z |
| format | Article |
| id | doaj.art-adbf4cec1313439286b72467c6d1fa8e |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-11T04:50:18Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-adbf4cec1313439286b72467c6d1fa8e2023-11-17T20:05:57ZengMDPI AGLife2075-17292023-04-0113495110.3390/life13040951Evolving Diagnostic and Management Advances in Coronary Heart DiseaseMatheus de Oliveira Laterza Ribeiro0Vinícius Machado Correia1Lucas Lentini Herling de Oliveira2Paulo Rogério Soares3Thiago Luis Scudeler4Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-010, BrazilInstituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-010, BrazilInstituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-010, BrazilInstituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-010, BrazilInstituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo 05403-010, BrazilDespite considerable improvement in diagnostic modalities and therapeutic options over the last few decades, the global burden of ischemic heart disease is steadily rising, remaining a major cause of death worldwide. Thus, new strategies are needed to lessen cardiovascular events. Researchers in different areas such as biotechnology and tissue engineering have developed novel therapeutic strategies such as stem cells, nanotechnology, and robotic surgery, among others (3D printing and drugs). In addition, advances in bioengineering have led to the emergence of new diagnostic and prognostic techniques, such as quantitative flow ratio (QFR), and biomarkers for atherosclerosis. In this review, we explore novel diagnostic invasive and noninvasive modalities that allow a more detailed characterization of coronary disease. We delve into new technological revascularization procedures and pharmacological agents that target several residual cardiovascular risks, including inflammatory, thrombotic, and metabolic pathways.https://www.mdpi.com/2075-1729/13/4/951coronary artery diseasecoronary interventionatherosclerosis |
| spellingShingle | Matheus de Oliveira Laterza Ribeiro Vinícius Machado Correia Lucas Lentini Herling de Oliveira Paulo Rogério Soares Thiago Luis Scudeler Evolving Diagnostic and Management Advances in Coronary Heart Disease Life coronary artery disease coronary intervention atherosclerosis |
| title | Evolving Diagnostic and Management Advances in Coronary Heart Disease |
| title_full | Evolving Diagnostic and Management Advances in Coronary Heart Disease |
| title_fullStr | Evolving Diagnostic and Management Advances in Coronary Heart Disease |
| title_full_unstemmed | Evolving Diagnostic and Management Advances in Coronary Heart Disease |
| title_short | Evolving Diagnostic and Management Advances in Coronary Heart Disease |
| title_sort | evolving diagnostic and management advances in coronary heart disease |
| topic | coronary artery disease coronary intervention atherosclerosis |
| url | https://www.mdpi.com/2075-1729/13/4/951 |
| work_keys_str_mv | AT matheusdeoliveiralaterzaribeiro evolvingdiagnosticandmanagementadvancesincoronaryheartdisease AT viniciusmachadocorreia evolvingdiagnosticandmanagementadvancesincoronaryheartdisease AT lucaslentiniherlingdeoliveira evolvingdiagnosticandmanagementadvancesincoronaryheartdisease AT paulorogeriosoares evolvingdiagnosticandmanagementadvancesincoronaryheartdisease AT thiagoluisscudeler evolvingdiagnosticandmanagementadvancesincoronaryheartdisease |